МОНОГРАФИЯ Гепатит и последствия гепатита. Майер К.-П (в word). Гепатит и последствия гепатита Практич рук. Пер с нем. Под ред. А. А. Шепулина. М. Гэотар медицина, 1999. 432 с
 Скачать 6.25 Mb.
|
|
JMolina, G Moraleda, A Moreno, JGarcia-Aguado, V Carreno Prospective, randomized controlled trial of interferon-alpha in children with chronic hepatitis В Hepatology 13 (1991) 135-139 Ruiz-Moreno, M , M J Rua, G Moraleda, L Guardia, A Moreno, V Carreno Treatment with interferon gamma versus interferons alfa and gamma in children with chronic hepatitis В Pediatncs 90 (1992) 254-258 Tine, F , A Liberati, A Craxi, P Almasio, L Pagliaro Interferon treatment in patients with chronic hepatitis В A meta-analysis of the published literature J Hepatol 18 (1993) 154-162 Tong, M J J S Nystrom, A G Redeker, G J Marshall Failure of transfer-factor therapy in chronic active type В hepatitis New Engl J Med 295 (1976) 209-211 Weller, J V D , V Carreno, M J F Fowler, J Monjardino, D Makinen, H С Thomas, S Sherlock Acyclovir inhibits hepatitis В virus replication in man Lancet 1982/1, 259 12-4 ХРОНИЧЕСКИЙ ВИРУСНЫЙ ГЕПАТИТ С Alberti, А , G Monsca, L Chemello, D Cavalletto, F Noventa, P Pontisso, A Ruol Hepatitis С viraemia and liver disease in symptom-free individuals with anti-HCV Lancet 340 (1992) 697-698 Andreone, P , С Cursaro, A Gramenzi, A Buzzi, R Miniero, G Sprovien, G Gasbarnni Indomethacin enhances serum 2"5"-oligoadenylate synthetase in patients with hepatitis В and С virus chronic active hepatitis Hepatol 21 (1994)984-988 Arber, N , M Moshkowitz, F KonikofT,Z Halpern,A Hallak, M Santo, E Tiom-ny, M Baratz, T Gilat Elevated serum iron predicts poor response to inter-feron treatment in patients with chronic HCV infection Dig Dis Sci 40 (1995) 243-2433B Bekkenng, Frank С J T Brouwer, G Leroux-Roels, H Van Vlierberghe, A Ele-waut, S W Schalm Ultrarap-id hepatitis С virus clearance by daily high-dose interferon in non-responders to standard therapy J Hepatol 28 (1998)960-964 Bellobuono, A , L Mondazzi, S Tempini, E Silini F Vican, G Ideo Ribavinn and interferon-a combination therapy vs interferon-ос alone in the re-treatment of chronic hepatitis С randomized clinical trial J Vir Hepatitis 4 (1997) 185-191 Berg, T, U Hopf Therapie der chronischen Virushepatitis Dtsch med Wschr 122 (1997)1593-1598 Blum, H E,K P Maier, G Strohmeyer Aktuelle Therapie der chronischen Virushepatitis Dtsch med Wschr 120 (1995) 295-300 Boyer, N , P Marcelhn, С Degott, F Degos, A G Saimot, S Eninger JP Benha-mou and the Comite des Anti-Viraux Recombinant interferon-a for chronic hepatitis С in patients positive for antibody to human immunodeficiency virus J Infect Dis 165 (1992) 723-726 BraconierJ H ,0 Paulsen, К Engman, A Widell Combined alpha-interferon and nbavmn treatment in chronic hepatitis С A pilot study Scand J Infect Dis 27 (1995) 325-329 Bnllanti, S , M Fob, S Gaiani, С Masci, M Miglioli, L Barbara Persistent hepatitis С viraemia without liver disease Lancet 341 (1993) 464-465 Bnllanti, S , M Miglioli, L Barbara Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders Italian experience Hepatol (Suppl 2) 23 (1995) 13-16 Cassani, F, M Cataleta, P Valentini, P Muraton, F Giostra, R Francesconi, L Muraton, M Lenzi, G Bianchi, D Zauli, F В Bianchi Serum autoantibo-dies in chronic hepatitis С Comparison with autoimmune hepatitis and impact on the disease profile Hepatology 26 (1997) 561-566 Chemello, L, L Cavalletto, E Bernardinello, M Guido, P Pontisso, A Alberti The effect of interferon alfa and nbavmn combination therapy in naive patients with chronic hepatitis С J Hepatol (Suppl 2)23 (1995) 8-12 Chemello, L, L Cavalletto, С Casann, P Bonetti, E Bernardinello, P Pontisso, С Donada, F Belussi, S Marti-nelh, A Alberti, and the Tn Veneto Viral Hepatitis Group Persistent hepatitis С viremia predicts late relapse after sustained response to interferon-a in chronic hepatitis С Ann Intern Med 124(1996)1058-1060 Chemello, L, P Bonetti, L Cavalletto, F Talato, V Donadon, P Casann, F Belussi, M Frezza, F Noventa, P Pontisso, L Benvegnu,С Casann, A Alberti, and the Tn Veneto Hepatitis Group Randomized trial com-panng three different regimes ofa!pha-2a-interferon in chronic hepatitis С Hepatology 22 (1995) 700-706 Colloredo, G , G Bellati, A Ricci, G Leandro, В Brugnetti, A Redaelli, A Bellobuono, F Bissoli, E Civardi, С Santambrogio, A Scalon, L Roffi, G Ideo Prediction of relapse after complete response to interferon for chronic hepatitis С J Hepatol (Suppl 1) 25(1996) 87 Colton, M , M Romano, M Persico, F Morisco, С Tuccillo, N Caporaso Hepatitis С virus RNA in serum and liver histology in asymptomatic anti-HCV positive subjects Infection 23 (1995) 33-37 Craxi, A , V Di Marco, С Camma, P Almasio, S Magnn Duration of HCV infection as a predictor of nonre-sponse to interferon Dig Dis Sci 41 (1996) 86S-92S Deutsch, M, S Dourakis, E К Manesis, A Gioustozi, G Hess, A Horsch, S Hadziyannis Thyroid abnormalities m chronic viral hepatitis and their relationship to interferon alfa therapy Hepatology 26 (1997) 206-210 DienstagJ L Management of chronic hepatitis С A consensus Gastroente-rology 113 (1997) 375 Dusheiko, G,H Schmilovitz-Weiss, D Brown, F Me Ornish, P-L Yap, S Sher-lock, N Me Intyre, P Sim-monds Hepatitis С virus genotypes an investigation of type-specific differences in geographic origin and disease Hepatology 19 (1994) 13-18 Enomoto, N , С Sato Clinical relevance of hepatitis С virus quasispecies J Vir Hepatit 2 (1995) 267-272 Fargion, S , A L Fracanzani, M Sampietro, V Molteni, R Boldonni, M Mattio-li, В Cesana, G Lunghi, A Piperno, С Valsecchi, G Fiorelli Liver iron influences the response to interferon alpha therapy in chronic hepatitis С Europ J Gastroenterol Hepatol 9 (1997)497-503 Gerken, G , G Teuber, В Goergen, К H Meyer zum Bnschenfelde Interferon-alpha retreatment in chronic hepatitisC J Hepatol (Suppl 1) 22 (1995)118-121 Gordon, S С Extrahepatic manifestations of hepatitis С Dig Dis 14(1996) 157-168 Cumber, S C,S Chopra HepatitisC A multifaceted disease Ann Intern Med 123 (1995) 615-620 Healey, С J , R W G Chapman, К A Fleming Liver histology in hepatitis С infection a comparison between patients with persistently normal or abnormal transaminases Gut 37 (1995) 274-278 Heinrich, D , К P Maier Behandlung der chronischen Virushepatitis mit Ace-thylsalicylsaure Schweiz Med Wschr 125 (1995) 755-757 Heller, J , J Musiolik, A Homnghausen, T Sauerbruch, U Spengler Vorkom-men und Bedeutung von Au-toantikorpern lm Rahmen der Interferonthe-rapie der chronischen Hepatitis С Dtsch med Wschr 121 (1996) 1179-1183 Helmreich-Вескег, I , W Godderz, W -J Mayet, К -H Meyer zum Bnschenfelde, A W Lohse Die Minilap-aroskopie in der Diagnostik chronischer Lebe-rerkrankungen Endoskopie heute 2 (1997) 195-200 Hensel, F J , T Heintges, W Petry, С Niederau, D Haussinger Verlaufsformen der chronischen Hepatitis С bei viralen Koinfektionen und zusatzhchen Lebererkrankungen Dtsch med Wschr 123 (1998) 161-166 Hermann, R , К P Maier Therapie der chronischen Hepatitis С bei Interferon-versagen Dtsch med Wschr 122 (1997) 1049-1054 Hinnchsen, H , W E Schmidt Interferone und Nukleosidanaloga Neue Per-spektiven in der Therapie chronischer Virushepatitiden Internist 39 (1998) 95-104 Hoofnagle,J H,A M Di Bisceglie The treatment of chronic viral hepatitis New Engl J Med 336(1997)347-3^6 Hopf, U , С Niederau, G Kleber, W E Fleig Behandlung der chronischen Virushepatitis B/D und der akuten und chronischen Virushepatitis С Z Ga-stroenteroL 35 (1997) 971-986 Houglum, К , A Venkataramani, К Lyche, M Chojkier A pilot study of the effects ofd-a-tocopherol on hepatic stellate cell activation in chronic hepatitis С Gastroenterology 113 (1997) 1069-1073 Ishak, К , A Baptista, L Bianchi, F Callea, J De Groote, F Gudat, H Denk, V Desmet, G Korb, R N M MacSween, M J Phillips, В G Portmann, H Poulsen, P J Scheuer, M Schmid, H Thaler Histological grading and staging of chronic hepatitis J Hepatol 22 (1995) 696-699 Kanno, Y J Toyota, M Sugawara, К Higashino, T Sato T Ohmura, T Suga, Y Okuuchi, T Matsushima Early loss of serum hepatitis С virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis С Am J Gastroenterol 92(1997)61-68 Kobayashi, Y, S Watanabe, M Konishi, M Yokoi, R Kakehashi, M Kaito, M Kondo, Y Hayashi, T Jc- mon, S Suzuki Quantitation and typing of serum hepatitis С virus RNA in patients with chronic hepatitis treated with inter-feron-P Hepatology 18 (1993) 1319-1325 Koizumi, К , N Enomoto, M Kurosaki, T Murakami, N Izumi, F Marumo, С Sato Diversity ofquasispecies in various disease stages of chronic hepatitis С virus infection and its significance in interferon treatment Hepatology 22 (1995) 30-35 Lai, M -Y J -H Kao, P -M Yang J -T Wang, P -J Chen, К -W Chan J -S Chu, D -S Chen Long-term efficacy of nbavmn plus interferon alfa in the treatment of chronic hepatitis С Gastroenterology 111 (1996) 1307-1312 Lam, N P,LJ De Guzman, D Pitrak T J Layden Clinical and histologic predictors of response to interferon- a in patients with chronic hepatitis С viral infection Dig Dis Sci 39 (1994) 2660-2664 Lindsay, К L, G L Davis, E R SchitT, H С Bodenheimer, L A Balart J L Diens-tag, R P Penllo, С H Tamburro, H S Goff, G T Everson, M Silva, W N Katkov, Z Goodman, J Y N Lau, G Maertens, J Gogate, В Sanghvi, J Al-brecht, and the Hepatitis Interventional Therapy Group Response to higher doses of interferon alfa-2b in patients with chronic hepatitis С A randomized multicenter tnal Hepatology 24 (1996) 1034-1040 Maier, К P Iron, HCVand the liver China NatLJ New Gastroenterol 3 (1997) 61-63 Manesis, E К , Ch Papajoannou, A Gioustozi, G Kafin, J Koskinas, S J Had-ziyannis Biochemical and virological outcome of patients with chronic hepatitis С treated with interferon alfa-2b for 6 or 12 months A 4-year-follow-up of 211 patients Hepatology 26 (1997) 734-739 Marcellin, P , N Boyer, J -P Behamou, S Eninger Interferon- cc therapy for chronic hepatitis С in special patient populations Dig Dis Sci 41 (1996) 126 S-130 S Marcellin, P , N Boyer, С Degott, M Martino-Peignoux, V Duchatelle, E Gio-stra, J Areias, S Ernnger, J -P Benhamou Long-term histologic and viral changes in patients with chronic hepatitis С who responedB to alpha interferon Liver 14 (1994) 302-307 Martinot-Peignoux, M , P Marcellin, M Pouteau, С Castelnau, N Boyer, M Poliquin, С Degott, I Descomb-es, V Le Breton, V Milotova J P Benhamou, S Ernnger Pretreatment serum hepatitis С virus RNA levels and hepatitis С virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis С Hepato-logy 22 (1995) 1050-1056 Michielsen, P P, E I Hauben, A M Ramon, E A Van Marck, P A Pelckmans Serum aminotransferase levels and histological disease in chronic hepatitis С Acta Gastro-Enterolog Belg 60 (1997) 11-14 Van Ness, M M , A M Diehl Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 111(1989) 473-478 Olynyk.J К , К R Reddy A M Di Bisceglie, L J Jeffers, T I ParkerJ L Radick, E R Schiff, В R Bacon Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis С Gastroenterology 108 (1995) 1104-1109 Pardo, M , 1 Castillo, H Oliva, A Fernandez-Flores, R Barcena, M A De Peut-ter, V Carreno A pilot study ofrecombinant interleukin-2 for treatment of chronic hepatitis С Hepatology 26 (1997) 1318-1321 Picciotto, A , G Varagona, F Valle, D A Coviello, G Lapertosa, G Celle Interferon therapy in chronic hepatitis С Evaluation of low dose maintenance schedule in responder patients Hepatol 17 (1993) 359-363 Poynard, T , P Bedossa, M Chevallier, P Mathunn, С Lemonnier, С Trepo, P Couzigou J L Payen, M Sajus J M Costa, M Vidaud J С Chaput and the Multicenter Study Group A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis New Engl J Med 332
Poynard, T , P Bedossa, P Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis С Lancet 349 (1997) 825-832 Poynard, T , V Leroy, M Cohard, T Thevenot, P Mathunn, P Opolon, J P Zar-ski Meta-analysis of interferon randomized trials in the treatment of viral hepatitis С effects of dose and duration Hepatology 24
Poynard, T,P Marcellin, S S Lee, Ch Niederau, G S Minuk, G Ideo, V Bain J Heathcote, St Zeuzem, Ch Trepo, J Albrecht Randomised trial of interferon cc2b plus ribavirin for 48 weeks or for 24 weeks versus interferon oc2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis С virus Lancet 352 (1998) 1426-1432 Pneto, M , V Olaso, С Verdu J Cordoba, С Gisbert, M Rayon, D Carrasco, M Berenguer, M D Higon, J Berenguer Does the healthy hepatitis С virus carrier state really exist? An analysis using polymerase chain reaction Hepatology 22 (1995) 413-417 Rambusch, E G,H Wedemeyer, H L Tillmann, S Hennglake, M P Manns Die Bedeutung einer Koinfek- tion mit dem Hepatitis-G-Virus flir die chro-nische Hepatitis - ein Review der Literatur Z Gastroenterol 36 (1998) 41-53 Rasi, G , D Di Virgiho, M G Mutchnick, F Colella, P Simbaldi-Vallebona, P Pienmarchi, В Valli, E Garaci Combination thymosinoci and lymphobla-stoid interferon treatment in chronic hepatitis С Gut 39 (19%) 679-683 Rossini, A , A Ravaggi, L Biasi, E Agostinelli, L Bercich, G В Gazzola, F Callea, E Radaeli E Canani Virological response to interferon treatment in hepatitis С virus carriers with normal aminotransferase levels and chronic hepatitis Hepatology 26 (1997) 1012-1017 Saez Royuela F ,J С Porres A Moreno, I Castillo, G Martinez, F Galiana, V Carreno High doses ofrecombmant ос-interferon ory-Interferon for chronic hepatitis С A randomized, controlled trial Hepatology 13 (1991) 327-331 Sangiovanni, A, R Morales, G С Spinzi, M G Rumi, A Casiraghi, R Сепаш, E Colombo, M Fossati, A Prada, E Tavani, G Minoh Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels A pilot randomized controlled study Hepatology 27 (1998) 853-856 Schalm, S W, J T Brouwer, L Chemello, A Alberti, A Bellobuono, G Ideo, R Schwartz, О Weiland Interferon-ribavirin combination therapy for chronic hepatitis С Dig Dis Sci 41 (1996) 131 S-134 S Schvarcz, R , Y Ando, A Sonnerborg, О Weiland Combination treatment with interferon alfa-2 b and ribavirin for chronic hepatitis С in patients who have failed to achieve sustained response to interferon alone Swedish experience Hepatol (Suppl 2) 23 (1995) 17-21 Serfaty, L, О Chazouilleres,J -M Pawlotsky, T Andreani, С Pellet, R Poupon Interferon-alfa therapy in patients with chronic hepatitis С and persistently normal aminotransferase activity Gastroenterology 110 (1996) 291 295 Shakil, А О , С Conry-Cantilena, H J Alter, P Hayashi, D E Kleiner, V Tedeschi, К Krawczynski, H S Conjeevaram, R Salhe, A M Di Bisceglie and the Hepatitis С Study Group Volunteer blood donors with antibody to hepatitis С virus clinical, biochemical, virologic, and histologic features Ann Intern Med 123 (1995) 330-337 Shiraton, Y, N Kato, О Yokosuka, F Imazeki, E Hashimoto, N Hayashi, A Na-kamura, M Asada, H Kuroda, N Tanaka, Y Arakawa, M Omata for theTo-kyo-Chiba Hepatitis Research Group Predictors of efficacy of interferon therapy in chronic hepatitis С virus infection Gastroenterology 113 (1997) 558-566 VanThiel, D H, L Fnedlander, R J Kama, PJ Molloy T Hassanein, H Faruki A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy J Vir Hepat (Suppl 1)4(1997) 101-106 Tong, M J,L M Blatt, J G Me Hutchison, R L Co, A Conrad Prediction of response during interferon alfa 2 b therapy in chronic hepatitis С patients using viral and biochemical characteristics a comparison Hepatology 26 (1997) 1640-1645 Tong, M J , N S El-Farra, A R Reikes, R L Co Clinical outcomes after transfusion-associated hepatitis С New Engl J Med 332 (1995) 1463-1466 Vial, TJ Descotes Clinical toxicity of the interferons Drug Safety 10 (1994) 115-150 Villa, E , P Buttafoco, A Menghi, A Grottola, I Ferretti, A Ferrari, F Callea, P Trande, A M Rebecchi, F Manenti Selection of more pathogenic hepatitis С virus genotyp II during long-term follow-up of interfe-ron-treated patients J Mol Med 73 (1995) 249-254 Willson, R A Extrahepatic manifestations of chronic viral hepatitis Am J Gastroenterol 92 (1997) 4-17 Yamada, G , M Takatani, F Kishi, M Takahashi, T Doi, T Tsuji, S Shin, M Tan-no, M S Urdea J A Kolberg Efficacy ofinterferon alfa therapy in chronic hepatitis С patients depends primarily on hepatitis С virus RNA level He-patology 22 (1995) 1351-1354 Yang, S -S , С -H Wu, С -S Huang, M -S Ho, M -Y Lai, J -H Kao, D -S Chen Early interferon therapy and abortion of posttransfusion hepatitis С viral infection Clin Gastroenterol 21(1995) 38-41 Yano, M , H Kumada, M Kage, К Ikeda, К Shimamatsu, О Inoue, E Hashimo-to J H Lefkowitch J Ludwig, К Okuda The long-term pathological evolution of chronic hepatitis С Hepatology23 (1996) 1334-1340 Zarski J -P , M Maynard-Muet, S Chousterman, M Baud, R Barnoud, A Aber-gel, Y Bacq J -M Combis, X Causse, A Tran, F Oberti, A Minello, S Bres-son-Hadni, F Bailly, J -J Raabe, V Leroy, L Hamici, T Hicham, M -F St Marc Girardin Tenoxicam, a non-steroid anti-inflammatory drug, is unable to increase the response rate in patients with chronic hepatitis С treated by alpha interferon Hepatology 27 (1998) 862-867 12-5 ХРОНИЧЕСКИЙ ВИРУСНЫЙ ГЕПАТИТ D Chossegros, P, T Fontanges, P Chevallier, M Chevalher, P Barlet, С Trepo HIV coinfection and chronic HDV hepatitis in drug addicts a dismal hepatic prognosis J HepatoL, Suppl 7 (1988) 21 Rizzeto, M.BH Hoyer, R H Purcell Hepatitis delta virus infection InVyas,GN,JL Dienstag,JH Hoofnagle Viral Hepatitis and Liver Disease Grune & Stratton, Or-lando, Florida 1984 (pp 371-378) Samuel, D , L Zignego, В Fabiani, D Castaing, С Serres, A Bismuth, M Reynes, J P Benhamou, С Brechot, H Bismuth Medium term results of liver transplantation in cirrhosis due to hepatitis delta virus (HDV) infection J HepatoL, Suppl 7 (1988) 75 12-6 АУТОИММУННЫЙ ХРОНИЧЕСКИЙ ГЕПАТИТ Czaja, A J , H V Ammon, W H J Summerskill Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission Gastroente rology 78 (1980) 518-523 Czaja, A J , J Rakela, J Ludwig Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis Gastroenterology 95 (1988) 448-453 Davis, G L , A J Czaja, J Ludwig Development and prognosis of histologic cirrhosis in corticosteroid treated hepatitis В surface antigen-negative chronic active hepatitis Gastroenterology 87 (1984) 1222-1227 Geubel, A Les manifestations systemiques de l'hepatic chroni-que aggressive Acta gastroenterol belg 37 (1974) 192-206 Johnson, P P , I G McFarlane and A L W F Eddleston The natural course and heterogeneity of autoimmune-type chronic active hepatitis Semin Liver Dis 11(1991)187-196 Johnson, P J , I G McFarlane Meeting report International autoimmune hepatitis group Hepatology 18 (1993) 998-1005 Keating, J J , С J O'Brien, A J Stellon Influence of aetiology, clinical and histological features on survival in chronic active hepatitis an analysis of 204 patients Quart J Med 237 (1987) 59-64 Mackinnon, M , W G E Cooksley, R A Smallwood Chronic hepatitis pathogenesis and treatment Austr J Med 16(1986) 101-107 Maddrey, W С , L Contos Therapeutic Concepts for the Management of Idiopathic Autoimmune Chronic Hepatitis Semin Liver Dis 11(1991) 248-255 Manns, M Autoantibodies and antigens in liver diseases-updated J Hepatol 9 (1989) 272-280 McFarlane, I G , J E Hegarty, С G McSorely, R Williams Antibodies to liver-specific protein predict outcome of treatment withdrawl in autoimmune chronic active hepatitis Lancet 1984/11, 954-956 Noun-Ana, С T , J E Hegarty, J Graeme, J M Alexander, F Eddleston, R Williams Effect of corticosteroids on suppressor-cell activity in "autoimmune*1 and viral chronic active hepatitis New Engl J Med 307 (1982) 301-304 Sanchez-Urdazpal, L , A J Czaja, В v Hoek, A F Ruud, Krom and Russell, H , J Wiesner Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis Hepatology 15 (1991) 215-221 Schaffner, F Autoimmune chronic active hepatitis three decades of progress InH Popper, F Schaffner Progress in Liver Disease Grune & Stratton, Orlando, Florida 1986 (p 485) Stellon, A J , A Davies, J Compston, R Williams Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy Gastroenterology 89 (1985) 1078-1083 Stellon, A J J E Hegarty, В Portmann, R Williams Randomised controlled trial of azathiopnne withdrawl in autoimmune chronic active hepatitis Lancet 1985/1, 668-670 Stellon, A J J J Keating, Hp J Johnson, I G McFanane, R Williams Maintenance of remission in autoimmune chronic active hepatitis with azathiopnn after corticosteroid withdrawl Hepatology 8 (1988) 781-784 Vento, S , J E Hegarty, G Bottazzo, R Williams, E Macchia, A L W F Eddleston Antigen specific suppressor cell function in autoimmune chronic active hepatitis Lancet 1984/1, 1200-1204 Zanger, U M , H -P Haun, J Loeper, J -C Homberg, U A Meyer Antibodies against human cytochrome P-450dbl in autoimmune hepatitis type II Proc nat Acad Sci 85 (1988) 8256-8260 12-7 БОЛЕЗНЬ ВИЛЬСОНА Brewer, G J , G M Hill, A A Prasad, Z T Cossack, P Rav-vani, A Arbor, A Park Oral zinc therapy for Wilson's disease Ann intern Med 99 (1983) 314-320 Brewer, G J , V Yuzbasiyan-Gurkan Wilson's disease an update, with emphasis on new approaches to treatment Dig Dis 7 (1989)178-193 Cailhe-Bertrand, M van, H J Degenhart, H К A Visser, M Sinaasappel, J Bouquet Oral zinc sulphate for Wilson's disease Arch Dis Childh 60 (1985) 656-659 Dubois, R S , D О Rodgerson, К M Hambidge Treatment of Wilson's disease with methylene tetramine hydrochloride (tnentine) J Pediat Gastroenterol Nutr 10(1990) 77-81 Hill, MG,GJ Brewer, AS Prasad, С R Hydnck, D E Hartmann Treatment of Wilson's disease with zinc I Oral zinc therapy regimens Hepatology 7 (1987) 522-528 Houwen, R H J , E A Roberts, G R Thomas, D W Cox DNA markers for the diagnosis of Wilson disease J Hepatol 17 (1993) 269-276 Lipsky, M A , J L Gollan Treatment of Wilson's disease In D-Penicillamine we trust - what about zinc? Hepatology 7 (1987) 593-595 Poison, R J , К Rolles, R Y Calne, R Williams, D Marsden Reversal of severe neurological manifestations of Wilson's disease following orthotopic liver transplantation QJ Med 244 (1987)685-691 Rakela, J, SB Kurtz, J T McCarthy, J Ludwig, N L Ascher, J R Bloomer, P L Claus Fulminant Wilson's disease treated with postdilution hemofiltration and orthotopic liver transplantation Gastroenterology 90 (1986) 2004-2007 Sandstedea, H H Zinc interference with copper metabolism J Amer med Ass 240 (1987) 2188-2189 Scheinberg I H , M E Jaffe, I Sternlieb The use of tnentine in preventing the effects of interrupting penicillamine therapy in Wilson's disease New Engl J Med 317 (1987) 209 212 Schilsky, М L,H Scheinberg, I Sternheb Prognosis of Wilso-nian chronic active hepatitis Gastroenterology 100 (1991) 762-767 Scheinberg, I H , I Sternheb Wilson's disease In Major problems in Internal Medicine, Vol XXIII Saunders, Philadelphia 1984 Stampefl, D A , S J Munoz, M J Montz, R Rubin, V T Armenti, В E Jarrell, W С Maddrey Heterotopic liver transplantation for fulminant Wilson's disease Gastroenterology 99 (1990) 1834-1836 Sternheb, I Wilson's disease transplantation when all else has failed Hepatology 8 (1988) 975-976 Sternheb, I Perspectives on Wilson's disease Hepatology 12 (1990) 1234-1239 Stremmel, W, К W Meyerrose, С Niederau, H Hefter, G Kreuzpaintner, G Strohmeyer Wilson disease Clinical presentation, treatment, and survival Ann intern Med 115 (1991) 720-726 Walshe, J M Treatment of Wilson's disease with tnentine (methylene tetramine) di hydrochloride Lancet (1982) 643 Walshe, J M Diagnosis and treatment of presymptomatic Wilson's disease Lancet 1988/11,435-437 12-8 ИДИОПАТИЧЕСКИЙ ГЕМОХРОМАТОЭ Adams, P С , M Speechley, A E Kerzesz Long-term survival analysis in hereditary hemochromatosis Gastroenterology 101 (1991) 368-372 Adams, P С , A E Kertesz, R Leslie, S Valberg Clinical presentation of hemochromatosis a changing scene Amer J Med 90(1991)445-449 Basset, ML, JW Halhday, R A Ferns, L W Powell Diagnosis of hemochromatosis in young subjects predictive accuracy of biochemical screening tests Gastroenterology 87 (1984) 628-633 Crawford, D H G , J W Halhday Current concepts in rational therapy for haemochromatosis Drugs 41
Edwards, С Q , L M Gnffen, D Goldgar, С Drummond, M Skolnick, J P Kushner Prevalence of hemochromatosis among 11,065 presumably healthy blood donors New Engl J Med 318 (1988) 1355 Edwards, С Q,J P Kushner Screening for hemochromatosis New Engl J Med 328 (1993)1616-1620 Edwards, С Q , L M Gnffen, J P Kushner Southern blood club symposium pdate on selected aspects of hemochromatosis Amer J med Sci 300(1990) 245-250 Fargion, S , С Mandelli, A Piperno, В Cesana, A L Francan-zani, M Fraquelh, P A Bianchi, G Fiorelh, D Conte Survival and prognostic factors in 212 Italian patients with genetic hemochromatosis Hepatology 15
Gollan, J L Diagnosis of hemochromatosis Gastroenterology 84 (1983) 418-431 Lin, E , P С Adams Biochemical liver profile in hemochromatosis A survey of 100 Patients J chn Gastroenterol 13 (1991) 316-320 Niederau, С , R Fischer, A Sonnenberg, W Stremmel, H J Trampisch, G Strohmeyer Survival and causes of death in cirrhotic and in non-cirrhotic patients with primary Hemochromatosis New Engl J Med 313 (1985) 1256-62 Pipemo, A , S Fargion, R D Alba, F Roffi, A L Fracanzani, L Vecchi, M Failla, G Fiorelh Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis В and С virus infection J Hepatol 16 (1992) 364-368 Salhe, RW,WD Reed, К В Shilkin Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic haemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis Gut 32 (1991) 208-210 Stremmel, W , С Niederau, G Strohmeyer Diagnose der pn-maren Hamochromatose Dtsch med Wschr 118
Stremmel, W, С Niederau, G Strohmeyer Therapie der Hamochromatose Dtsch med Wschr 118(1993)267-269 Vierhng, J M Epidemiology and clinical course of liver disease identification of candidates for hepatic transplantation Hepatology 4 (1984) 845-945 12-9 ПЕРВИЧНЫЙ БИЛИАРНЫЙ ЦИРРОЗ ПЕЧЕНИ A European Multicentre Study Group The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis J Hepatol 17 (1993) 227-235 Bachs, L, A Pares, M Elena, С Piera, J Rodes Effects of long-term nfampicin administration in primary biliary cirrhosis Gastroenterology 102 (1992) 2077-2080 Balasubramaniam, К , P M Grambsch, R H Wiesner, К D Lindor, E R Dickson Asymptomatic primary biliary cirrhosis (PBC) patients have a diminished survival Hepatology 7 (1987) 1025 (abstract) Batts, К P , R A Jorgensen, E R Dickson, A F Hofmann, S S Rossi, J Ludwig, К D Lindor The effects of ursode-oxychohc acid on hepatic inflammation and histologic stage in patients with pnmary biliary cirrhosis Hepatology 18 (1993) 175A Beswick, David R , G Klatskin, J L Boyer Asymptomatic primary biliary cirrhosis A progress report on long-term follow-up and natural history Gastroenterology 89 (1985) 267-271 Beukers, R , S W Schalm Immunosuppressive 'herapy for primary biliary cirrhosis J Hepatol 14(1992)1-6 Bodenheimer, II, F Schaffner, J Pezzullo Evaluation ofcol-chicme therapy in primary biliary cirrhosis Gastroenterology 95 (1988) 124-129 Chnstensen, E , J Neuberger, J Crowe, D G Altmann, II Popper, В Portmann, D Doniach, L Ranek, N Tygstrup, R Williams Beneficial effect of azathiopnne and prediction of prognosis in primary biliary cirrhosis Gastroenterology 89(1985) 1084-1091 Combes, В , R L Carithers, W С Maddrey, S J Munoz, M F McDonald, G Garcia-Tsao, J L Boyer, V Luketic, M Shiffman, M G Peters, II White, R Zetterman, R Markm A randomized, double-blind, placebo-controlled trial of urso-deoxychohc acid (UDCA) in primary biliary cirrhosis Hepatology 18 (1993) 175A Esquivel, Carlos О , David II vanThiel, Anthony J Demetns, Angel Bernardos, Shunzaburo Iwatsuki, Bernd Markus, Robert D Gordon, J Walhs Marsh, Leonard Makowka, An-dreas G Tzakis, SatoruTodo, Judith S Gavaler, Thomas E Starzl Transplantation for primary biliary cirrhosis Gastro-enterology94 (1988) 1207-1216 Floreani, A , M Chiaramonte, S Giannim, L Malvasi, M G Lodetti, R Castngnano, A Giacomini, A D 'Angelo, R Naccarato Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment J Hepatol 12 (1991) 217-223 Ghent, С N ,S G Carruthers Treatment of pruritus in primary biliary cirrhosis with Rifampin, results of a double-blind, crossover, randomized trial Gastroenterology 94 (1988) 488-493 Hoofnagle, J II, G L Davis, D F Schafer, M Peters, M I Avigan, S С Pappas, R G Hanson, G Y Minuk, GM Dusheiko, G Campbell, N Roderick, M Macsween, E A Jones Randomized trial of chlorambucil for primary biliary cirrhosis Gastroenterology 91 (1986) 1327-1334 Kaplan, M M , D W Ailing, Ph D Hyman, J Zimmermann, II J Wolfe, R A Sepersky, G S Hirsch, G II Eita, К A Ghck, А К Eagen A prospective trial of colchicine for primary biliary cirrhosis New Engl J Med 315 (1986) 1448-1454 Kaplan, M , M Grace, II Eita, Bruce Fune, James A Sadows-ki, Robert M Russell Fat-soluble vitamin nutn-ture in primary cirrhosis Gastroenterology 95 (1988) 787-792 (abstract) Kaplan, M M,T A Knox Effective treatment of pre-cin hotic primary biliary cirrhosis (PBC) with methorex-ate (MTX) remission in some Hepatology 10 (1989) 585 (abstract) Kaplan, M M ,T A Knox Treatment of primary biliary cirrho-sis with low-dose weekly methotrexate Gastroenterology 101 (1991) 1332-1338 Klein, R , P A Berg Prognostische Bedeutung der antimito-chondrialen Antikorper-Profile A-D bei primar-biharer Zir-rhose Dtsch med Wschr 113 (1988) 1549-1553 Kneppelhout, J С , С J J Mulder, G P van Berge Henegou-wen, R A de Vnes, К II Brandt Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease Neth J Med 41 (1992) 11-16 Leuschner, U , FL Fischer, W Kurtz, S Gnldutuna, К Htibner, A Hellstern, M Gatzen, M Leuschner Ursodeoxycholic acid in primary biliary cirrhosis results of a controlled double-blind trial Gastroenterology 97 (1989) P68-1274 Lombard, M , В Portmann, J Neuberger, R Williams, N Tygstrup, L Ranek, Ft Ring-Larsen, J Rodes, M Navasa, С Trepo, G Pape, G Schou, J FL Badsberg Cyclosporin A treatment m primary biliary cirrhosis Results of a long-term placebo controlled trial Gastroenterology 104 (1993) 519-526 Mackay, I R , M E Gershwin Primary biliary cirrhosis current knowledge, perspectives, and future directions Semin Liver Dis 9 (1989)149-157 Matloff, D S , M M Kaplan, R M Neer, M J Goldberg, W Bitman,H J Wolfe Osteroprosis in primary biliary cirrhosis effects of25-hydroxyvitamin D3 treatment Gastroenterology 83 (1982) 97-102 Minuk, G Y , С E Bohme, E Burgess, N В Hershfield, J К Kelly, E A Schaffer, L R Sutherland, G van Rosendaal Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis Gastroenterology 95 (1988) 1356-1363 (abstract) Mitchison, II, MF Bassendine, A J Malcolm, A J Watson, CO Record, OFW James Apilot, double-blind, controlled 1-year trial of Prednisolone treatment in primary biliary cirrhosis hepatic improvement but greater bone loss Hepatology 10 (1989) 420-429 Mitchision, H С , J M Palmer, M F Bassendine, A J Watson, С О Record, OFW James A controlled trial ofpred-msolone treatment in primary biliary cirrhosis Three-year results J Hepatol 15 (1992) 336-344 Neuberger, J , E Chnstensen, В Portmann, J Caballena, J Rodes, L Ranek, N Tygstrup, R Williams Double-blind controlled trial of D-Penicillamme m patients with primary biliary cirrhosis Gut 26(1985) 114-119 Nyfcerg, A , В Berne, II Nordhnder, С Busch, U Eriksson, L Loof, A Fahlquist Impaired release of vitamin A from liver in pnmary biliary cirrhosis Hepatology 8 (1988) 136-141 Perdigoto, R , R II Wiesner Progression of primary biliary cirrhosis with Ursodeoxycholic acid therapy Gastroenterology 102 (1992) 1389-1391 Poison, R J , В Portmann, J Neuberger, R Y Calne, R Williams Evidence for disease recurrence after liver transplantation for primary biliary cirrhosis Clinical and histologic follow-up studies Gastroenterology 97 (1989) 714-725 Poupon, R , R Е Poupon, Y Calmus, Y Chretien, F Ballet, F Darms Is Ursodeoxycholic acid an effective treatment for primary biliary cirrhosis9 Lancet 1987/11, 834-836 Poupon, R E , В Balkau, E Eschwege, R Poupon, UDCA-PBC Study Group A multicenter, controlled trial of ursodio! for the treatment of primary biliary cirrhosis New Engl J Med 30(1991)1584-1554 Raedsch, R , A Stiehl Ursodesoxycholsaure - Em neuesThe-rapiekonzept bei cholestatischen Leberkrankheiten Klin Wschr 67 (1989) 265-268 Roll, J, J L Boyer, D Barry, G Klatskm The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis New Engl J Med 308 (1983)1-7 Sokol, R J , Y S Kirn, J H Hoofnagle, J E Heubi, A A Jones, W F Bahsten Intestinal malabsorption of vitamin E in primary biliary cirrhosis Gastroenterology 96 (1989) 479-486 Vogel, W , H Kathrem, G Judmaier, H Braunstemer Deterioration of primary biliary cirrhosis during treatment with Ursodeoxycholic acid Lancet 1988/1,1163 (abstract) Warnes, T W , A Smith, F Lee et al A controlled trial of colchicine in primary biliary cirrhosis Trial design and preliminary report J Hepatol 5 (1987) 1-7 Wiesner, R H , P M Gramsch, К D Lindor, J Ludwig, E R Dickson Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis Hepatology 8 (1988) 668-676 Wiesner, RH.J Ludwig, К D Lindor, R A Jorgense, W P Baldus, II A Homburger, E R Dickson A controlled trial of cyclosponne in the treatment of primary biliary cirrhosis New Engl J Med 322(1990)1419-24 12-10. ПЕРВИЧНЫЙ СКЛЕРОЗИРУЮЩИЙ ХОЛАНГИТ Aadland, E,E Schrumpf, О Fausa, К Elgjo, A Heilo, I Aakus, E Gjone Primary sclerosing cholangitis a long-term follow-up study Scand J Gastroenterol 22 (1987) 655-664 Balasubramaniam, К , R II Wiesner, N F LaRusso Primary sclerosing cholangitis with normal serum alkaline Phosphata-se activity Gastroenterology 95 (1988) 1395-1398 Beuers, U , U Spengler, W Kruis, U Aydemir, В Wiebecke, W Heldwem, M Wemzien, G R Pape, T Sauer-bruch, G Paumgartner Ursodeoxycholic acid for treatment of primary sclerosing cholangitis A placebo-controlled trial Hepatology 16 (1992) 707-714 CameronJ L ,H A Pitt Resection of hepatic duct bifurcation and transhepatic stentmg for sclerosing cholangitis Ann Surg 207(1988)614-622 Cangemi, JR.RH Wiesner, S J Beaver Lack of effect of proctocolectomy on the natural history of primary sclerosing cholangitis Gastroenterology 90 (1986) 1364 Cangemi, J R , R H Wiesner, S J Beaver, J L R L MacCar-ty, R R Dozois, A R Zmsmeister, N F LaRusso Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis Gastroenterology 96 (1989) 790-794 Craig, P I, A R W Hatfiled Endoscopic therapy in primary sclerosing cholangitis Europ J Gastroenterol Hepatol 4 (1992) 284-287 Dickson, E R , P A Murtaugh, R H Wiesner, P M Grambsch, T R Fleming, J Ludwig, N F Larusso, M Ma-linchoc, R W Champman, M M Kaplan, W С Maddrey, R Williams, M Farrant, A Langworthy Primary sclerosing cholangitis refinement and validation of survival models Gastroenterology 103 (1992) 1893-1901 Duerr, R II, S R Targan, G J Landers, N F Larusso, К L Lindsay, R II Wiesner, F Shanahan Neutrophil cytoplas-mic antibodies A link between primary sclerosing cholangitis and ulcerative colitis Gastroenterology 100 (1991) 1385-1391 Farrant, M , R Williams Natural history and prognosis in primary sclerosing cholangitis Europ J Gastroenterol Hepatol 4(1992) 272-275 Farrant, J M , К M Hayllar, M L Wilkinson, J Karani, В С Protmann, D WestabyandR Williams Natural history and prognostic variables in primary sclerosing cholangitis Gastroenterology 100 (1991) 1710-1717 Gomez, R L , M D J W Griffin jr , J E Squires Prolonged relief of intractable pruritus in primary sclerosing cholangitis by plasmapheresis, J elm Gastroenterol 8 (1986) 301-303 Hay, J E , К D Lindor, R II Wiesner, E R Dickson, RAF Krom, N F Larusso The metabolic bone disease of primary sclerosing cholangitis Hepatology 14 (1991) 257-261 Helsberg, J H , J M Petersen, J L Boyer Improved survival with primary sclerosing cholangitis A review of chnicopathologic features and comparison of symptomutic and asympto-matic patients Gastroenterology 92 (1987) 1869-75 Herrmann, R , J Dooley, S Sherlock, N Mclntyre Progression of asymptomatic primary sclerosing cholangitis (PSC) J Hepatol, Suppl 7(1988) 39 Iwatsuki, S T E Starzl, D vanThiel Liver transplantation for primary sclerosing cholangitis Gastroenterology 90 (1986) 1736 Kaplan, M M Medical approaches to primary sclerosing cholangitis Semin Liver Dis 11(1991) 56-63 Kaplan, М М , S Агога, S II Pincus Primary sclerosing cholangitis and low-dose oral pulse methotrexate therapy Ann intern Med 106 (1987) 231-235 Klein, R, J Eisenburg, P Weber, F Seibold, P A Berg Significance and specificity of antibodies to neutrophils detected by Western Blotting for the serological diagnosis of primary sclerosing cholangitis Hepatology 14 (1991) 1147-1152 Knox, T A , M M Kaplan Treatment of Primary Sclerosing Cholangitis with Oral Methotrexate Amer J Gastroenterol 86 (1991) 546-552 LaRusso, N , R Wiesner, J Ludwig, R Maccarty, S Beaver, A Zinsmeister, J King Randomized trial of penicillamine in primary sclerosing cholangitis Gastroenterology 95 (1988) 1036-1042 Lebovics, E , M Palmer, J Woo, F Schaffner Outcome of primary sclerosing cholangitis Arch intern Med 147 (1987) 729-731 McGanty, B, DS Bansi, D A F Robertson, G II MiUward-Sadler, II A Sherpherd Primary sclerosing cholangitis an important and prevalent complication ofchron's disease Europ J Gastroenterol Hepatol 3
Marsh, J W , S Iwatsuki, L Markowka, M D Esquivel, R D Gordon, S Todo, A Tzakis С Miller, D van Thiel, ТЕ Starzl Orthotopic liver transplantation for primary sclerosing cholangitis Ann Surg 207 (1988) 21-25 O'Brien, С В, J R Senir, R Arora-Mirchandani, A Batta, G Salen Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis A 30-month pilot study Hepatology !4 (1991) 838-847 Porayko, M К , N F Larusso, R II Wiesner Primary sclerosing cholangitis A progressive disease? Semin Liver Dis 11 (1991) 18-25 Seibold, F , P Weber, R Klein, P A Berg, К II Wiedmann Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis Gut 33(1992)657-662 Wiesner, R II, S J Beaver, J Ludwig, N F LaRusso The natural history of symptomatic and asymptomatic primary sclerosing cholangitis Gastroenterology 909 (1986) 1780-1785 Wiesner, R II Advances in therapy for primary sclerosing cholangitis Europ J Gastroenterol Hepatol 4
Wiesner, R H , P Grambsch, N L LaRusso, E R Dickson Is primary sclerosing cholangitis a progressive disease or not? Hepatology 8 (1988) 970-972 Wiesner, RIl.MK Poraxko, E R Dickson, G J Gores, N F Larusso, J E Hay, II E Wahlstrom, RAF Krom Selection and timing of liver transplantation in primary biliary cirrhosis and primary sclerosing cholangitis Hepatology 16(1992) 1290-1299 14-1 КРОВОТЕЧЕНИЕ ИЗ ВАРИКОЗНЫХ ВЕН ПИЩЕВОДА Burroughs, А К Portal hypertension and vanceal bleeding Curr Opin Gastroenterol 8 (1992) 388-397 Cello, J P , J II Grendell, R A Crass, T E Wever, D D Trunkey Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute vanceal hemorrhage New Engl J Med 318 (1987) 11-15 Conn, HO Transjugular intrahepatic portal-systemic shunts The state of the art Hepatology 17 (1993) 148-158 Editorial Italian Multicenter Project Propanolol for prophylaxis of bleeding in cirrhotic patients with large varices a Multi-center, randomized clinical tnal Hepatology 1 (1988) 1-5 Editorial North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices Prediction of the first van-eel hemorrhage in patients with cirrhosis of the liver and esophageal vances New Engl J Med 319 (1988)983 Eriksson, L S Medical and surgical treatment of acute bleeding form esophageal varices in patients with cirrhosis Scand J Gastroenterol 26(1991) 897-908 Fleig, WE,EF Stange, W Schonborn, D Wordehoff, G Preclik, R Nuber, К Rainer, II Ditschuneit Propranolol (P) versus endoscopic sclerotherapy (EPS) for the prevention of recurrent hemorrhage in cirrhosis final analysis of a randomized clinical trial Hepatology 7 (1987) 355-361 Gimson, A E S , J К Ramage, M Z Panos, К Hayllar, P M Harrison, R Williams, D Westaby Randomized trial of vanceal banding ligation versus injection scleiotherapy for bleeding oesophageal varices Lancet 342
Gines, P, E Quintero, V Arroyo, J Teres, M Bruguera, A Rimola, J Caballeria, J Rodes, С Rozman Compensated cirrhosis natural history and prognostic factors Hepatology 1 (1987) 122-128 Molstege, A, J Scholmench Therapie und Prophylaxe der Osophagusvanzenblutung Z Gastroenterol 28 (1990) 302-314 Ideo G , G Belldti, E Fesce, D Grimoldi Nadolol can prevent the first gastrointestinal bleeding in cirrhotics a prospective, randomized study Hepatology 1 (1988) 6-9 Infante-Rivard, С , S Esnaola, J -P Villeneuve Role ofendo-scopic vanceal sclerotherapy in the long-term management of vanceal bleeding a meta-analysis Gastroenterology 96 (1989) 1087-1092 Inokuchi, К , and cooperative study group of portal hypertension of japan Improved survival after prophylactic portal mondetompression surgery for esophageal varices A randomized clinical trial Hepatology 12 (1990)1 6 Korula, J, L A Balart, G Radvan, В E Zweiban, A W Larson, H W Kao, S Yamada A prospective, randomized controlled trial of chronic esophageal vanceal sclerotherapy Hepatology 4 (1985) 584-589 Macdougall, R R D , A Theodossi, D Westaby, J L Daw-son Increased long-term survival in vanceal haemorrhage using injection sclerotherapy Lancet 16 (1982) 124 McCormick, P A , G L Kaye, L Greenslade, F Cardin, KEF Hobbs, N Mclntyre, А К Burroughs Esophageal staple transection as a salvage procedure after failure of acute injection sclerotherapy Hepatology 15 (1992) 403-406 Orloff, MJ.RH Bell Emergency portacaval anastomosis (EPCA) the long-awaited trial Gastroenterology 90 (1986) 1754 (abstract) Paquet, К -J , H Feussner Endoscopic sclerosis and esophageal balloon tamponade in acute hemorrhage from esophago-gastnc varices a prospective controlled randomized trial Hepatology 4 (1985) 580-583 Pascal, J P , P Cales Propranol in the prevention of first upper gastrmtestmal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices New Engl J Med 14 (1987) 856-861 Rossle, M,G Noldge, К Haag, M Sellinger, A Ochs, U Blum, V Siegerstetter, P Deibert, JM Perarnau, M Lan-ger, W Gerok Technik, Indikationen und klinische Ergeb-nisse des transjugularen intrahepatischen portosystemischen Stent-Shunts Med Welt 44 (1993) 439-444 Santangelo, W, M Dueno, В Estes, G Krejs Prophylactic sclerotherapy of large esophageal varices New Engl J Med 319 (1988) 813-818 Sarin, S К , R Nanda, G Sachdev, S Charim, В S Anand, S L Broor Intravanceal versus paravariceal sclerotherapy a prospective, controlled, randomized trial Gut 28 (1987) 657-662 Sauerbruch, T , H Ansan, R Wotzka, N Soehendra, W Kopcke Prognose-Parameter bei Leberzirrhose, Van-zenblu-tung u Sklerosierungstherapie Dtsch med Wschr 113 (1988)11-14 Sauerbruch, T , G Paumgartner Prophylaxe der Osophagusvanzenblutung Internist (1987) 459-467 Sauerbruch, T , R Wotzka, W Kopcke, M Harlin, W Held-wein, E Bayerdorffer, R Sander, H Ansan, I Starz, G Paumgartner Prophylactic sclerotherapy before the first episode of vanceal hemorrhage in patients with cirrhosis New Engl J Med 319(1988) 8-15 Soderlund, С Long-term survivors after vanceal haemorrhage Scand J Gastroenterol 22 (1987) 665-671 Stiegmann, G V, J S Goff, P A Michaletz-Onody, J Korula, D Liebermann, Z A Saeed, R M Reveille, J H Sun, S R Lowenstein Endoscopic sclerotherapy as compared with en-doscopic ligation for bleeding esophageal varices New Engl J Med 326 (1992) 1527-1532 Terblanche, J , D Kahn,J A Campbell, P С Bornman, M A T Jonker, J Wright, R Kirsch Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal vanceal bleeding Lancet 1983/ 1,1328-1332 Teres, J , R Baroni, J M Bordas, J Visa, С Pera, J Rodes Randomized tnal of portacaval shunt, stapling transection and endoscopic sclerotherapy in uncontrolled vanceal bleeding J Hepatol 4 (1987)159-167 Westaby, D The management of active vanceal bleeding J Hepatol 17 (Suppl 2) 1993 34-37 Westaby, D , P С Hayes, A E S Gimson, R J Poison, R Williams Controlled clinical trial of injection sclerotherapy for active vanceal bleeding Hepatology 2 (1989) 274-277 Westaby, D , В Macdougall, R Williams Improved survival following injection sclerotherapy for esophageal varices final analysis of a controlled trial Hepatology 5 (1985) 827-830 14-2 ПЕЧЕНОЧНАЯ ЭНЦЕФАЛОПАТИЯ Bansky, G,PJ Meier, E Riederer, H Walser, W H Ziegler, M Schmidt Effects of the Benzodiazepine receptor antagonist Flumazeml in hepatic encephalopathy in humans Gastro-enterology 97 (1989) 744-750 Beh, AT Hepatic encephalopathy In Kaplowitz N (ed) Liver and Biliary Diseases Williams & Wilkins, Baltimore 1992 (p 552) Bircher, J , W Sommer Portal-systemic encephalopathy In Pneto, J , J Rodes, D A Shafntz (eds ) Hepatobiliary Diseases Springer, Berlin 1992 (p 417) Conn, О , С M Leevy, Z R Vlahcevic, J В Rodgers, W С Maddrey, L Seeff, L L Levy Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy Gastroenterology 72 (1977) 573-583 Daly, JM, MH Mihraman, J E Kehoe, M F Brennan Effects of postoperative infusion of branched chain amino acids on nitrogen balance and forearm muscle substrate flux Surgery 94 (1983) 151-158 Eriksson, L S , A Presson, J Wahren Branched chain amino acids in the treatment of chronic hepatic encephalopathy Gut 23 (1982) 801-806 Ferenci, P Treatment of hepatic encephalopathy by benzodia-zepine receptor antagonists In Rodes, J , V Arroyo (eds ) Ediciones Doyma, S A , Barcelona 1992 (p 302) Ferenci, P , G Grimm Benzodiazepinantagonisten in der Be-handlung der hepatischen Enzephalopathie Leber Magen Darm 6 (1989) 322-325 Freund, H , J Dienstag, J Lehnch, N Yoshimura, R Bradford, H Rosen, S Atamian, E Slemmer, J Holroy-de, J E Fischer Infusion of branched-chain ennched amino acid solution in patients with hepatic encephalopathy Ann Surg 196 (1982) 209-220 Gerok, W Hepatische Encephalopathy Therapie mit adap-tierten Aminosauren- und Ketosaurengemischen Therapie-woche 34 (1984) 49-62 Kabadi, U M The association of hepatic glycogen depletion with hyperammonemia in cirrhosis Hepatology 5 (1987) 821-824 Kleinberger, G Parenterale Ernahrung bei Lebennsuffizienz Schweiz med Wschr 116 (1986) 545-549 Maier, К -P Progress in the treatment of portal-systemic encephalopathy (PSE) J Hepatol 5 (1987) 355-361 Maier, К-P Diagnose der hepatischen Enzephalopathie Dtsch med Wschr 113 (1988) 1882-1885 Maier, К-P Therapie der hepatischen Enzephalopathie Dtsch med Wschr 113 (1988) 1886-1889 Maier, K-P,W Gerok Hyperammonemia and hepatic ence-phalopathy Internal Symposium nber Ammoni- akstoffwech-sel Karger, Basel 1984 (S 224) Marchesini, G , M Zoli, С Dondi, G Bianchi, M Cirulli, E Pisi Anticatabohc effect of branched-chain amino acid-enriched solutions in patients with liver cirrhosis Hepatology 2 (1982) 420-425 McCullough, A J ,X D Mullen, A S Tavill Branched-chain amino acids as nutritional therapy in liver disease dearth or surfeit? Hepatology 3 (1983) 269-271 Michel, H , M Solere, P Granier, G Cauvet, J P Ball, F Pons, H Bellet-Hermann Treatment of cirrhotic hepatic en-cephalopathy with L-Dopa A controlled trial Gastroenterol-ogy 79 (1980) 207-211 Morgan, M Y The treatment of chronic hepatic encephalopa-thy Hepato-Gastroenterol 38 (1991) 377-387 Morgan, M Y,K E Hawley Lactitol vs lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients a double-blind, randomized trial Hepatology 6 (1987) 1278-1284 Morgan, M Y , К E Hawley, D Stambuk Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy a double-blind, randomised, cross-over study J Hepatol 4(1987) 236-244 Morgan, M Y , J P Mi'son, S Sherlock Plasma ratio ofvaline, leucine and isoleucine to phenylalanine and tyrosine in liver disease Gut 19 (1978) 1068-1073 Morgan, M H , A E Read D С Speller Treatment of hepatic encephalopathy with metronidazole Gut 23 (1982) 1-7 j Mullen, К D , F L Weber Role of nutrition in hepatic encephalopathy Semin Liver Dis 11 (1991) 292-304 Petndes, A S , W Stremmel Hepatische Enzephalopathie Diagnostische und therapeutische Moglichkeiten Verdau-ungskrankheiten 9 (1991) 192-198 Plauth, M , E H Egberts Was ist gesichert in der Therapie der hepatischen Enzephalopathie? Internist 33 (1992) 1-9 Shaw, S , T M Worner, С S Lieber Comparison of animal and vegetable protein sources in the dietary management of hepatic encephalopathy Amer J clin Nutr 38 (1983) 59-63 Sushma, S , S Dasarathy, R К Tandon, S Jain, S Gupta, M S Bhist Sodium benzoate in the treatment of acute hepatic encephalopathy A double-blind randomized trial Hepatology 16(1992) 138-144 Unbe, M , О Campollo, F Vargas, G P Ravelh, F Mundo, L Zapata, S Gil, G Garcia-Ramos Acidifying enemas (lactitol and lactose) vs nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy a double-blind, randomized clinical trial Hepatology 4 (1987) 639-643 Unbe, M , S Gil, F Bosques, E Huerta Hyperammonemic hepatic encephalopathy treated with sodium benzoate Final report of a double-blind evaluation Hepatology 4 (1989) 589-590 Weber, F L , В J Reiser Relationship of plasma amino acids to nitrogen balance and portal-systemic encephalopathy in alcoholic liver disease Dig Dis |